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Abstract
Objective: To evaluate predictors of undergoing fertility preservation treatment (FPT) in women
with breast cancer.
Design: Secondary analysis of a clinical database.
Setting: Three academic fertility preservation centers.
Patient(s): One hundred and eight patients with breast cancer undergoing FPT and 77 patients
with breast cancer not undergoing FPT from 2005-2010.
Intervention(s): None.
Main Outcome Measure(s): Patients’ demographic and medical information.
Result(s): Women who had FPT were older, wealthier, and had lower cancer stage compared to
women who did not have FPT. The rate of the administration of neoadjuvant chemotherapy
(NAC) was significantly lower in women who underwent FPT. After adjusting for age, BMI,
income, cancer stage, and center, a negative correlation persisted between NAC and FPT
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Capsule
Several factors are associated with undergoing fertility preservation treatment. Understanding these factors may be helpful to better
target counseling and possibly tailor treatments so that FPT options can be maximized.
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(OR=0.091, 95 % CI 0.009-0.904). When we stratified the women by center, women at Center-1
had a significantly lower FPT rate, lower parity, higher BMI, more advanced cancer stage, and
lower income compared to Centers-2 and -3. The rates of NAC were significantly higher in
Center-1.
Conclusion(s): While age, BMI, income, cancer stage, center and NAC appear to be associated
with undergoing FPT, NAC is the only modifiable variable. Since NAC restricts the time available
for FPT, oncologists may consider offering adjuvant chemotherapy, except in cases where NAC
clearly improves survival, in women who are interested in FPT.
Keywords
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INTRODUCTION
Increasing survival rates after breast cancer have heightened the importance of quality of life
issues, including fertility preservation treatment (FPT), defined as embryo or oocyte
cryopreservation. Oncologists are increasingly aware of the importance of discussing
reproductive issues with patients and referring appropriate patients to fertility preservation
specialists. Because oncologists have the essential role of initiating the discussion about
FPT, the American Society of Clinical Oncology (ASCO) and American Society of
Reproductive Medicine (ASRM) have developed guidelines about this topic (1, 2).
Specifically, the guidelines suggest that oncologists “should address the possibility of
infertility with patients treated during their reproductive years and be prepared to discuss
possible fertility preservation options or refer appropriate and interested patients to
reproductive specialists”. Currently, many academic institutions offer FPT and oncologists
collaborate with fertility preservation specialists for prompt referrals and treatments. As a
result, an increasing number of patients are referred to fertility preservation specialists.
However, not all referred patients ultimately undergo FPT. For example, a recent study of 70
European infertility centers showed that only 7.6% of breast cancer patients referred to
fertility specialists before chemotherapy initiation underwent FPT (3). Considering that
patients who elect to have a fertility preservation consultation (FPC) are likely interested in
their fertility after cancer treatment, it is notable that a minority of patients underwent FPT,
despite initial consultation.
Many factors may influence a patient’s decision to pursue FPT. Parity, educational
background, income, and prior knowledge about fertility preservation options have been
found to influence the decision to pursue FPT (3-6). Other factors, such as cancer treatment
plans (adjuvant versus neoadjuvant chemotherapy), prognosis and physician encouragement,
could possibly influence a patient’s choice about FPT (7, 8). Nonetheless, data on the
characteristics of women with breast cancer who ultimately undergo FPT are limited.
Understanding predictors of FPT may help identify systemic-wide patterns that affect
likelihood of utilization of assisted reproductive techniques. Potentially, providers could
potentially tailor their referral patterns for FPT based on these predictors, and/or modify
practice patterns to allow all interested women to participate in these opportunities. The aim
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of this study was to assess factors associated with FPT in patients with newly diagnosed
breast cancer at three large academic hospitals.
MATERIALS AND METHODS
We performed a secondary analysis of a clinical database of women with breast cancer
undergoing FPC prior to chemotherapy between January 2005 and December 2010 from
three academic centers in three different states (Center-1: University of North Carolina at
Chapel Hill, NC, Center-2: Institute for Fertility Preservation, NY, Center-3: University of
Pennsylvania, PA). The inclusion criteria were as follows: age ≤ 42; availability of complete
data about the date of the FPC, date of chemotherapy initiation; and cancer stage I-III.
Data regarding patients’ demographic and medical information were abstracted from
medical records. Estimated annual income was calculated through an income tax database
by home zip code (9). Distance from the clinic was calculated as the distance between the
patient’s home zip code and the clinic zip code. FPT utilization rate was calculated as the
number of the patients who received FPT divided by the number of the total patients
included.
Analysis was performed with SPSS 17 (SPSS, Chicago, IL). Continuous data (presented as
mean ± standard deviation) was analyzed by ANOVA, t- test or Mann-Whitney U test as
appropriate. Categorical data was analyzed using χ2 or Fisher’s exact tests as appropriate. A
two tailed P <0.05 was considered statistically significant. Multivariable logistic regression
models were constructed to evaluate the association between pursuing FPT and clinical and
treatment characteristics, including the administration of neoadjuvant chemotherapy (NAC).
RESULTS
The exact dates for FPC and initiation of chemotherapy were available in 236 patients. Of
those, 51 were excluded (33 were older than 42, 11 were stage 0 (ductal carcinoma in situ),
2 were stage 4, and stage was not available in 5 women). 185 women met all inclusion
criteria. Of those, 36 were from Center-1, 116 were from Center-2, and 33 were from
Center-3. Of the 185 patients, 108 patients (58.4%) underwent FPT. In univariate analysis,
the FPT group had a lower mean BMI, was wealthier, and had lower cancer stage compared
to the group that did not undergo FPT (Table 1). The rate of administration of NAC was
significantly lower in women in the FPT group. Age, parity, BRCA mutation status, history
of infertility, family history of breast/ovarian cancers, and hormone receptor status of cancer
were not different between women who underwent FPT and those who did not. The
likelihood of having insurance coverage or a partner was not different between the two
groups.
Of the 108 patients who underwent FPT, 90 patients (83.3%) underwent embryo
cryopreservation, 10 (9.3%) underwent oocyte cryopreservation, and 8 (7.4%) underwent
both. Of those, 97 (89.8%) were stimulated with letrozole-gonadotropin protocol, 7 (6.4%)
with antagonist protocol, and 4 (3.7%) with luteal phase long protocol. In Center-1 and -3,
letrozole-gonadotropin protocol was used principally in patients who had estrogen receptor
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positive cancer, however, in Center-2 letrozole-gonadotropin protocol was used regardless
of estrogen receptor status (Table 3).
Women in Center-1, compared to Centers-2 and -3, had a significantly fewer nulliparous
patients (50%, 87.1% and 89.5% respectively, p= 0.009) and a lower FPT utilization rate
(27.8%, 70.7%, and 48.5% respectively, p < 0.001). Compared to Center-2, patients at
Centers-1 and -3 were significantly younger and had lower estimated income. The rates of
lymph node involvement and administration of NAC were significantly higher in Center-1
(Table 2). IVF treatment outcomes defined as number of oocytes or embryos cryopreserved
were not different among the three centers (Table 3).
Figure 1 illustrates that women who underwent NAC had only an average of 14 days (range,
6 to 26 days) between FPC and initiation of chemotherapy, as opposed to 55 days for
women who had surgery first. Among the 19 patients who received NAC, only 1 patient
from Center-2 underwent FPT. In multivariable logistic regression models, a negative
association persisted between NAC and FPT (OR= 0.091, 95 % CI 0.009-0.904) after
adjusting for BMI, income, center and cancer stage. Mean time from FPC to oocyte retrieval
was 32 days (range, 9 to 69 days).
DISCUSSION
In this multi-center analysis, we evaluated variables associated with the likelihood of
pursuing FPT. BMI, income, cancer stage, center, and NAC appear to predict the likelihood
of undergoing FPT. Interestingly, receiving NAC was associated with not undergoing FPT,
even when we controlled for other significant variables. Predictors differed by Center;
Center-1 had the lowest utilization rate of FPT and the highest rate of administration of
NAC compared to Centers-2 and -3.
We found that several variables are related to utilization of FPT. First, BMI was lower in the
FPT group compared to the no-FPT group, though this may be confounding, as BMI has
been reported to have a significant positive correlation with stage of cancer (10). Second, a
higher annual income logically correlates with increased FPT utilization, as FPT may be
cost-prohibitive for those without insurance coverage and low income. Third, patients with
more advanced disease were less likely to undergo FPT; these patients may need to quickly
proceed with cancer treatments and/or have less concern about quality of life issues. Fourth,
each center had different rates of FPT utilization. Several factors should be considered to
interpret this finding. For example, each center’s physicians might counsel the patients in
different ways. Also, each center had a different rate of administration of NAC (NAC is
used broadly under study protocol’s at Center-1). Fifth, we found that women in the FPT
group trended to be older, compared to women in the no-FPT group (p=0.05). We can
speculate that, generally, older patient may be more stable financially or regarding
relationships, and therefore FPT may be a more feasible option in this age-bracket. In
addition, parity in the FPT group had tendency to be lower compared to the no-FPT group
(p=0.05). This finding is similar to study reporting that women who were childless at the
time of their cancer treatments were more likely to undergo counseling and treatment with
FPT (3).
Kim et al. Page 4






















One of our most novel findings was that NAC was a negative predictor of FPT even after
adjusting other significant variables, which may be related to time-constraints, safety
concerns, or characteristics of patients who receive NAC. First, there is a short time interval
between diagnosis and the initiation of NAC. Generally, NAC is preferred in patients with
advanced disease and patients planning NAC initiate treatment soon after cancer diagnosis
(11, 12). Thus, these patients would have only a limited time window for ovarian
stimulation. Several studies have shown that if the time interval between breast cancer
surgery and adjuvant chemotherapy is as long as 12 weeks, there is no detrimental effect on
survival or recurrence, compared to women who have a shorter time interval (13, 14).
However, to date, there are no studies that show the effect of delaying the initiation of NAC
on treatment outcome in women with breast cancer and therefore, we are not proposing
delaying NAC for FPT. Our data demonstrate that the mean time interval from FPC to the
initiation of NAC was 14 days. Considering that FPT protocol takes approximately two
weeks but initiation depends on the woman’s cycle (15), 14 days is likely insufficient time
for FPT. However, the mean time interval from cancer diagnosis to FPC was 18 days in the
patients who underwent NAC, indicating that if the patient was referred for FPC earlier (e.g.
immediately after diagnosis), she may have enough time for FPT prior to NAC, without
delaying the start of chemotherapy. In our data, there was only one patient who underwent
FPT followed by NAC and she was referred only 3 days after her cancer diagnosis,
consistent with a recent study by Lee et al. demonstrating the benefit of early referral in
patients with cancer (16). The current study only includes women who presented for FPC;
however, it is possible that a significant number of women who were planning NAC did not
consider a FPC at all or the oncologists treating these women did not refer them for FPC,
due to perceived time constraints.
Another possible reason that NAC may negatively predict FPT is related to safety concerns.
To date, there is only one study that evaluated the safety of FPT in breast cancer patients
(17). This study demonstrated no increased risk of recurrence (hazard ratio 0.56, 95% CI
0.17 to 1.9), and no difference in relapse-free survival (p=0.36) with FPT with letrozole-
gonadotropin protocol in women receiving adjuvant chemotherapy after initial surgery,
though “overall survival” was not a reported outcome. The median follow-up after
chemotherapy was 23.4 months (range, 7.5 to 63.6 months) in the women who underwent
FPT and 33.05 months (range, 4.5 to 63.6) in the women who did not undergo FPT.
However, the risks associated with FPT in women receiving NAC (with the primary tumor
in place) are unknown. Future studies about the feasibility and safety of FPT in breast cancer
patients before the initiation of NAC are needed. That being said, if a patient is interested in
FPT, working with the oncology team to alter treatment plan (for example pursing adjuvant
vs. NAC, when survival outcomes are equivalent) can allow interested women the
opportunity to pursue FPT.
Finally, the characteristics of patients who receive NAC may help explain the negative
association between NAC and FPT. In general, NAC is the preferred treatment for patients
with inoperable inflammatory or locally advanced breast cancer (stage IIIa and above) since
it has several advantages in this subgroup of patients. These advantages may include
allowing patients with inoperable cancers to become candidates for surgical resection (11,
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12), targeting clinically occult micro-metastases (18), and providing an opportunity to
deliver cytotoxic agents to the tumor with intact native vasculature (19). Also, several
studies have shown that NAC is tolerable and significantly improves outcomes compared to
surgery alone in patients who had inflammatory or locally advanced breast cancer (20, 21).
Since NAC tends to be offered to patients with advanced disease, perhaps our finding that
NAC is a negative predictor of FPT may be related to the fact that oncologists treating
women with advanced cancer defer the discussion about fertility issues when the prognosis
is poor (22). However, we find in multivariate regression models that NAC has an
independent inverse association with pursing FPT, even after controlling for cancer stage
and other significant predictors from our univariate analysis. Another interesting finding was
that NAC has a broader use under research protocols at Center-1, and a higher utilization
rate at that institution, even in lower stage breast cancers. At Center-1, only 35.2 % of the
patients in NAC group met the informal criteria (inoperable inflammatory or locally
advanced breast cancer) for NAC use (21, 23). On the other hand, NAC was used only with
advanced stage cancers at Centers 2 and 3, where only 3 patients received NAC, all of
whom had stage III disease, large tumors (4-6 cm) and lymph node involvement. Given this
data, we conclude that NAC is an independent negative predictor of FPT in women with
breast cancer.
Our study is unique for several reasons. This is the first study to evaluate which variables
predict the utilization of FPT in patients with breast cancer. While there are a few studies
assessing the characteristics of female patients counseled for fertility preservation (3, 24), no
study investigated predictors of treatments. Second, this is a multi-center study which
involves three tertiary academic hospitals in three different states. This enables our study to
evaluate patients with a wide variety of socio-demographic backgrounds. Third, we confined
the definition of FPT to embryo and/or oocyte cryopreservation and more than 90% of FPT
group underwent embryo cryopreservation. We believe that this is a clinical significant
outcome to study, as embryo cryopreservation is the most established assisted reproductive
technique for fertility preservation for female patients (1). Other studies have included
experimental fertility preservation techniques when assessing utilization, such as GnRH-
agonist treatment and ovarian tissue cryopreservation (3), even though these options have
not been proven to improve fertility chances.
Our study has several limitations. Since it was conducted retrospectively, the specific
reasons that contribute to the patient’s decision to undergo FPT cannot be ascertained.
Another limitation is that annual income and insurance information is estimated based on the
patient’s zip code, which may limit accuracy. Other variables, such as education level and
patient comprehension of FP choices, were not available. Subtle differences in cancer
treatments and oncology attitudes at different centers are difficult to assess and may
influence the decision to pursue FPT.
To our knowledge, this is the first multi-center study that shows the predictors of pursuing
FPT in patients with breast cancer. Specifically, here we report for the first time that
administration of NAC is an independent negative predictor of FPT. NAC restricts the time
available for FPT. It is noteworthy that while BMI, income, cancer stage, and NAC appear
to predict the likelihood of undergoing FPT, NAC is the only “modifiable’ variable in
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certain patients. The use of NAC varies by center – Center-1 has a broader use of NAC
under research protocols and many patients who received NAC had early stage of disease
(stage I-II). In general, while NAC can alter surgical options, allowing women to undergo a
lumpectomy rather than a mastectomy, the lack of survival benefit of NAC compared to
adjuvant chemotherapy has been demonstrated (25-27). Except in cases where NAC clearly
improves survival, oncologists may consider offering adjuvant chemotherapy, rather than
NAC, in women who are interested in FPT. Surgery prior to chemotherapy may be an option
for these patients, giving them time to pursue FPT.
In conclusion, we found that several factors are associated with undergoing FPT and
administration of NAC was the only modifiable and independent negative predictor.
Understanding these factors may help oncologists and fertility preservation specialists to
better target counseling and possibly tailor treatments so that FPT options can be
maximized.
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Comparison of clinical course between patients who underwent NAC and did not undergo
NAC. (A) Clinical course of the patients who underwent NAC and no FPT. (B) Clinical
course of the patients who had adjuvant chemotherapy and FPT. (C) Clinical course of the
patients who had adjuvant chemotherapy, but did not undergo FPT.
NAC indicates neoadjuvant chemotherapy; FPC, fertility preservation consultation; FPT,
fertility preservation treatment; OR, oocyte retrieval.
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Table 1







 Age (years) 36.1±4.3 34.7±5.2 0.05
 BMI (Kg/m2) 23.2±4.1 25.5±5.9 0.02
 Nulliparity (%) 83.8 71.4 0.05
 Income (USD/year) 150,323 ± 139,807 95,677 ± 93,290 0.002
 Distance to clinic (miles) 135.2±415.5 96.6±355.9 0.52
  Time from initial diagnosis to FPC
(days)
50.8±76.3 46.2±71.9 0.7










   I-II 96.3 83.6 0.01
   III 3.7 16.4
 Size (cm) 1.9±1.1 2.0±1.1 0.71




 Lymph node positive (%) 70.7 62.9 0.336
 NAC use (%) 2.7 31.0 <0.001
Note: FPT = fertility preservation treatment; FPC = fertility preservation consultation; NAC = neoadjuvant chemotherapy.
a
Data from Center-1 (n=36) and Center-3 (n=33) only.
b
Either ER and/or PR.
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Table 2

































 Distance to clinic (miles) 63.4±61.5 165.0±489.5 22.6±19.3





   I-II 82.6 95.1 87.5
   III 17.4 4.9 12.5
 Size of cancer (cm) 1.6±0.7 2.0±1.2 2.1±1.1
 Hormone Receptor positive* (%) 68.6 80.2 75
































Either ER and/or PR.
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Table 3



















No. of patients stimulated with












Mean no. of oocytes retrieved 10.7±6.5 15.4±9.4 15.6±9.4
Mean no. of oocytes fertilized 4.7±4.7 7.6±5.0 6.7±5.2






Mean no. of oocytes
 cryopreserved N/A
* 8.1±10.8 6.8±4.4
Mean no. of embryos
 cryopreserved 3.8±3.2 7.6±6.6 6.8±5.2




















No patient underwent oocyte cryopreservation.
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